Limits...
Rituximab therapy in Greek patients with rheumatoid arthritis.

Tsiakalos AP, Avgoustidis NK, Moutsopoulos HM - Biologics (2008)

Bottom Line: Statistical analysis has shown no differences in clinical response, between RF positive/negative patients, and anti-CCP-positive/negative patients, while decline of RF was better correlated with reduction of DAS-28 than with anti-CCP.Rituximab is a well tolerated and effective treatment in RA.Decline of RF was associated with clinical response and reduction of DAS-28 and CRP.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathophysiology, Medical School, National Univercity of Athens, Athens, Greece.

ABSTRACT

Objective: An open-label, prospective, uncontrolled study created to investigate clinical response, serological changes and side effects in Greek patients with rheumatoid arthritis (RA), after B-cell depletion with rituximab.

Methods: Patients with high disease activity (disease activity score [DAS]-28 > 5.1) were selected for treatment with rituximab and received two infusions, 1 gr each, 2 weeks apart. Different disease parameters (visual analog scale, DAS-28, C-reactive protein [CRP], erythrocyte sedimentation rate, health assessment questionnaire, complement (C3), C4, rheumatoid factor [RF], anti-cyclic citrullinated peptide antibody [anti-CCP], swollen joint count, tender joint count, immunoglobulin M [IgM], IgG, IgA) were performed at base line, 2, 4, and 6 months post-treatment. Response was defined according to the American College of Rheumatology (ACR) criteria.

Results: Seventeen patients received therapy. Treatment led to a reduction in various disease parameters. ACR20 was achieved in 41.11% of patients by week 8, 52.94% by week 16, and 82.35% by week 24. ACR50 was achieved in 5.88% by week 8, 41.17% by week 16, and 64.7% by week 24. ACR70 was achieved only by week 24 in 23.52% of patients. Statistical analysis has shown no differences in clinical response, between RF positive/negative patients, and anti-CCP-positive/negative patients, while decline of RF was better correlated with reduction of DAS-28 than with anti-CCP.

Conclusions: Rituximab is a well tolerated and effective treatment in RA. Response was not correlated to RF or anti-CCP positivity. Decline of RF was associated with clinical response and reduction of DAS-28 and CRP.

No MeSH data available.


Related in: MedlinePlus

Immunoglobulin levels during rituximab therapy.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2727907&req=5

f4-btt-2-911: Immunoglobulin levels during rituximab therapy.

Mentions: Total serum Igs decreased moderately during follow up. Their mean values remained within normal levels (Figure 4).


Rituximab therapy in Greek patients with rheumatoid arthritis.

Tsiakalos AP, Avgoustidis NK, Moutsopoulos HM - Biologics (2008)

Immunoglobulin levels during rituximab therapy.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2727907&req=5

f4-btt-2-911: Immunoglobulin levels during rituximab therapy.
Mentions: Total serum Igs decreased moderately during follow up. Their mean values remained within normal levels (Figure 4).

Bottom Line: Statistical analysis has shown no differences in clinical response, between RF positive/negative patients, and anti-CCP-positive/negative patients, while decline of RF was better correlated with reduction of DAS-28 than with anti-CCP.Rituximab is a well tolerated and effective treatment in RA.Decline of RF was associated with clinical response and reduction of DAS-28 and CRP.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathophysiology, Medical School, National Univercity of Athens, Athens, Greece.

ABSTRACT

Objective: An open-label, prospective, uncontrolled study created to investigate clinical response, serological changes and side effects in Greek patients with rheumatoid arthritis (RA), after B-cell depletion with rituximab.

Methods: Patients with high disease activity (disease activity score [DAS]-28 > 5.1) were selected for treatment with rituximab and received two infusions, 1 gr each, 2 weeks apart. Different disease parameters (visual analog scale, DAS-28, C-reactive protein [CRP], erythrocyte sedimentation rate, health assessment questionnaire, complement (C3), C4, rheumatoid factor [RF], anti-cyclic citrullinated peptide antibody [anti-CCP], swollen joint count, tender joint count, immunoglobulin M [IgM], IgG, IgA) were performed at base line, 2, 4, and 6 months post-treatment. Response was defined according to the American College of Rheumatology (ACR) criteria.

Results: Seventeen patients received therapy. Treatment led to a reduction in various disease parameters. ACR20 was achieved in 41.11% of patients by week 8, 52.94% by week 16, and 82.35% by week 24. ACR50 was achieved in 5.88% by week 8, 41.17% by week 16, and 64.7% by week 24. ACR70 was achieved only by week 24 in 23.52% of patients. Statistical analysis has shown no differences in clinical response, between RF positive/negative patients, and anti-CCP-positive/negative patients, while decline of RF was better correlated with reduction of DAS-28 than with anti-CCP.

Conclusions: Rituximab is a well tolerated and effective treatment in RA. Response was not correlated to RF or anti-CCP positivity. Decline of RF was associated with clinical response and reduction of DAS-28 and CRP.

No MeSH data available.


Related in: MedlinePlus